Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) EBT (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed EBT for 9 consecutive years, with -$5.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBT rose 38.83% year-over-year to -$5.7 million, compared with a TTM value of -$38.5 million through Jun 2025, down 38.26%, and an annual FY2025 reading of -$26.7 million, up 32.84% over the prior year.
  • EBT was -$5.7 million for Q2 2025 at VYNE Therapeutics, up from -$8.6 million in the prior quarter.
  • Across five years, EBT topped out at -$5.6 million in Q1 2023 and bottomed at -$19.9 million in Q2 2021.
  • Average EBT over 5 years is -$9.4 million, with a median of -$8.8 million recorded in 2021.
  • The sharpest move saw EBT skyrocketed 88.12% in 2021, then plummeted 100.25% in 2024.
  • Year by year, EBT stood at -$8.8 million in 2021, then grew by 12.15% to -$7.7 million in 2022, then grew by 20.61% to -$6.2 million in 2023, then tumbled by 95.25% to -$12.0 million in 2024, then soared by 52.15% to -$5.7 million in 2025.
  • Business Quant data shows EBT for VYNE at -$5.7 million in Q2 2025, -$8.6 million in Q1 2025, and -$12.0 million in Q4 2024.